Blood and Marrow Transplantation Reviews: Breakthrough Therapies for Acute Graft-Versus-Host-Disease

Release date: June 30, 2017
Expiration date: June 30, 2018

Program Overview

This activity will provide focused instruction to healthcare professionals caring for patients with Graft-Versus Host Disease (GVHD). The activity is designed to provide clinically relevant updates on the treatment of patients with hematologic malignancies likely to undergo allogeneic stem cell trans-plantation. The activity will focus on increasing clinician knowledge and the ability to integrate changes into practice to improve patient outcomes. The program will highlight the changes in treatment that acute GVHD is experiencing due to recent implications of clinical trials and breakthrough designations of target agents. Topics for presentation will include: the antigens and microbiome characteristics involved in GVHD in addition to biomarkers for GVHD.

Learning Objectives

The following are the learning objectives in CME format for this program. Upon completion of this program, participants will be able to:

• Describe the overall clinical understanding of the pathophysiology, guidelines, and patient risk factors for GVHD
• Evaluate novel treatment options, especially breakthrough therapies, for GVHD
• Identify the importance of biomarkers for GVHD and the progress on finding more effective options

Target Audience

This activity has been developed and is intended for transplant specialists, oncologists, hematologists and other healthcare professionals involved in the treatment of patients with GVHD.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and Carden Jennings Publishing Co., Ltd. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

This enduring material is approved for one year from the date of original release, June 30, 2017 to June 30, 2018.

Off-Label/Investigational Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Medical College of Wisconsin, or Carden Jennings Publishing.

Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically, and are encouraged to consult appropriate resources for any product or device mentioned in this activity.

CJP Medical Communications Disclosure

The employees of CJP Medical Communications have no financial relationships to disclose.

Faculty Disclosures

Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:

James Ferrara, MD, DSc discloses that he received royalties for a GVHD Biomarker patent and has intellectual property rights.
Motoko Koyama, MD, PhD has nothing to disclose.
Ernst Holler, MD, PhD discloses that he has been on the Advisory Board for Pharmacyclics. He also received honoraria from Prime Oncology and Sanofi.
John R. Wingard, MD, has no relevant financial relationships to disclose.
Nosha Farhadfar, MD, has no relevant financial relationships to disclose.